{"id":70754,"date":"2026-05-12T10:43:33","date_gmt":"2026-05-12T10:43:33","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=70754"},"modified":"2026-05-21T07:14:10","modified_gmt":"2026-05-21T07:14:10","slug":"mazdutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/mazdutide\/","title":{"rendered":"Mazdutide"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is Mazdutide?<\/h3>\n

Mazdutide<\/strong> (developmental codes IBI362 \/ LY3305677) is a long-acting dual GLP-1 and glucagon receptor co-agonist peptide developed by Innovent Biologics (in-licensed from Eli Lilly). It is the first dual GLP-1\/glucagon agonist to reach Phase 3 trials in obesity and type 2 diabetes, with the glucagon component adding an energy-expenditure mechanism beyond what GLP-1-only and GLP-1\/GIP-dual peptides produce. Plasma half-life supports once-weekly dosing. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials for laboratory research use only.<\/p>\n<\/div>\n

Wat u krijgt bij MedsBase:<\/strong> Onderzoekskwaliteit lyofiliseerde peptiden \u00b7 HPLC \u226599% zuiverheid (COA op aanvraag) \u00b7 Discrete temperatuurstabiele verpakking \u00b7 Wereldwijde peptidekoerier \u00b7 1.400+ geverifieerd klantbeoordelingen<\/a><\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specificatie<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
CAS-nummer<\/strong><\/td>\n2376247-09-1 (mazdutide; commonly cited)<\/td>\n<\/tr>\n
Type<\/strong><\/td>\nLong-acting dual GLP-1 \/ glucagon receptor co-agonist (acylated synthetic peptide; Innovent IBI362 \/ Eli Lilly LY3305677; oxyntomodulin-derived scaffold)<\/td>\n<\/tr>\n
Moleculair gewicht<\/strong><\/td>\n~4,865 Da (with fatty-acid acylation; published mature form)<\/td>\n<\/tr>\n
Structure<\/strong><\/td>\nSynthetic peptide based on the natural oxyntomodulin scaffold (the endogenous dual GLP-1\/glucagon agonist), with engineered substitutions for DPP-4 resistance and a fatty-diacid acyl tether attached at a lysine residue via a \u03b3-Glu linker. The acyl chain drives reversible serum-albumin binding that produces the extended weekly half-life.<\/td>\n<\/tr>\n
Form<\/strong><\/td>\nLyofiliseerd poeder (wit tot off-white)<\/td>\n<\/tr>\n
Zuiverheid<\/strong><\/td>\n\u226599% (HPLC geverifieerd, COA op aanvraag)<\/td>\n<\/tr>\n
Opslag<\/strong><\/td>\nLyofiliseerd: 2\u20138 \u00b0C (koelkast) voor werkvoorraad; \u221220 \u00b0C voor langdurige opslag van ongeopende flesjes. Gereconstitueerd: 2\u20138 \u00b0C, gebruik binnen ~30 dagen. Bescherm tegen licht. Vries de gereconstitueerde oplossing niet in en ontdooi deze niet.<\/td>\n<\/tr>\n
Oplosbaarheid<\/strong><\/td>\nBacteriostatic water (recommended) or sterile water for shorter use windows. Acylated peptides may dissolve more slowly \u2014 allow extra equilibration time.<\/td>\n<\/tr>\n
Onderzoeksgebruik<\/strong><\/td>\nAlleen voor laboratoriumonderzoek. Niet voor humaan of veterinair diagnostisch of therapeutisch gebruik.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is Mazdutide?<\/h2>\n

Mazdutide<\/strong> is a long-acting synthetic dual GLP-1 and glucagon receptor co-agonist developed under the developmental codes IBI362 (Innovent Biologics, in-licensed from Eli Lilly LY3305677). It is one of the most advanced compounds in the renewed wave of oxyntomodulin-derived dual-agonist pharmacology \u2014 an approach distinct from both the GLP-1-only programme (semaglutide) and the GLP-1\/GIP dual-agonist programme (tirzepatide). The structural inspiration is oxyntomodulin itself, a 37-amino-acid product of preproglucagon processing in intestinal L-cells that natively activates both the GLP-1 and glucagon receptors. Endogenous oxyntomodulin has very short pharmacokinetics; mazdutide engineers around this with a fatty-acid acyl tether at a lysine residue that drives reversible serum-albumin binding and extends the plasma half-life sufficiently for once-weekly subcutaneous administration in clinical research.<\/p>\n

Mazdutide has a mature molecular weight of approximately 4,865\u00a0Da including the acyl modification. The structural scaffold preserves the dual-receptor pharmacology of oxyntomodulin while engineered substitutions confer resistance to DPP-4-mediated proteolytic cleavage that would otherwise produce rapid clearance. Mazdutide is the lead Chinese metabolic peptide programme, with Phase 3 trials (GLORY-1 in obesity, DREAMS-1 and DREAMS-2 in type 2 diabetes) reporting body-weight reductions of approximately 15\u201317% at the highest dose tier over 48 weeks. Outside China, mazdutide is niet goedgekeurd<\/strong> by the FDA, EMA, MHRA, or any other major Western regulator. In China, mazdutide has been approved by the NMPA under its initial commercial brand \u2014 making it one of the first dual-agonist incretin peptides to receive regulatory clearance for human use anywhere. The research-grade mazdutide sold here is supplied uitsluitend voor laboratoriumonderzoek<\/strong> and is not intended for human or veterinary administration. For the triple-agonist comparator that adds GIP on top of the same GLP-1\/glucagon combination, see our Retatrutide<\/a> product page.<\/p>\n

Mechanism of Action \u2014 Dual GLP-1 \/ Glucagon Receptor Co-Agonism<\/h2>\n

What makes mazdutide mechanistically distinctive among current dual-agonist metabolic peptides is that it pairs the canonical GLP-1 satiety \/ glycaemic axis with the glucagon receptor energy-expenditure axis<\/strong> \u2014 not the GIP receptor axis used by tirzepatide. The dual-receptor profile produces complementary effects across three principal compartments documented in published research:<\/p>\n